Expression of Raf Kinase Inhibitor Protein (RKIP) is a predictor of uveal melanoma metastasis

Histology and Histopathology

Volumn 29, Issue 10, 2014, Pages 1325-1334

  Caltabiano, Rosario ^a   Puzzo, Lidia ^a   Barresi, Valeria ^b   Cardile, Venera ^a   Loreto, Carla ^a   Ragusa, Marco ^a   Russo, Andrea ^a   Reibaldi, Michele ^a   Longo, Antonio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Immuno histochemistry; pRKIP; RKIP; Uveal melanoma

Indexed keywords

PEBP1 PROTEIN, HUMAN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; UVEA TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 84907246351     PISSN: 02133911     EISSN: 16995848     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Akaishi J., Onda M., Asaka S., Okamoto J., Miyamoto S., Nagahama M., Ito K., Kawanami O. and Shimizu K. (2006). Growth suppressive function of phosphatidylethanolamine-binding protein in anaplastic thyroid cancer. Anticancer Res. 26, 4437-4442.
2. Al-Mulla F., Hagan S., Behbehani A.I., Bitar M.S., George S.S., Going J.J., García J.J., Scott L., Fyfe N., Murray G.I. and Kolch W. (2006). Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J. Clin. Oncol. 24, 5672-5679.
3. Al-Mulla F., Bitar M.S., Taqi Z., Rath O. and Kolch W. (2010). RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol. Biosyst. 7, 928-941.
4. Allegra E., Caltabiano R., Amorosi A., Vasquez E., Garozzo A. and Puzzo L. (2013). Expression of BMI1 and p16 in laryngeal squamous cell carcinoma. Head Neck 35, 847-851.
5. Baritaki S., Chapman A., Yeung K., Spandidos D.A., Palladino M. and Bonavida B. (2009). Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 28, 3573-3585.
6. Buzzacco D.M., Abdel-Rahman M.H., Park S., Davidorf F., Olencki T. and Cebulla C.M. (2012). Long-term survivors with metastatic uveal melanoma. Open Ophthalmol. J. 6, 49-53.
7. Chatterjee D., Bai Y., Wang Z., Beach S., Mott S., Roy R., Braastad C., Sun Y., Mukhopadhyay A., Aggarwal B.B., Darnowski J., Pantazis P., Wyche J., Fu Z., Kitagwa Y., Keller E.T., Sedivy J.M. and Yeung K.C. (2004). RKIP sensitizes prostate and breast cancer cells to drug induced apoptosis. J. Biol. Chem. 279, 17515-17523.
8. Collaborative Ocular Melanoma Study Group. (2001). Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15 Arch. Ophthalmol. 119, 670-676.
9. Corbit K.C., Trakul N., Eves E.M., Diaz B., Marshall M. and Rosner M.R. (2003). Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol.Chem. 278, 13061-13068.
10. Das S.K., Bhutia S.K., Sokhi U.K., Azab B., Su Z.Z., Boukerche H., Anwar T., Moen E.L., Chatterjee D., Pellecchia M., Sarkar D. and Fisher P.B. (2012). Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma. Cancer Res. 72, 6217-6226.
11. Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Yao Z. and Keller E.T. (2003). Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer. Inst. 95, 878-889.
12. Gangemi R., Mirisola V., Barisione G., Fabbi M., Brizzolara A., Lanza F., Mosci C., Salvi S., Gualco M., Truini M., Angelini G., Boccardo S., Cilli M., Airoldi I., Queirolo P., Jager M.J., Daga A., Pfeffer U. and Ferrini S. (2012). Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS One 7, e29989.
13. Greten F.R. and Karin M. (2004). The IKK/NF-kappaB activation pathway: A target for prevention and treatment of cancer. Cancer Lett. 206, 193-199.
14. Harbour J.W., Onken M.D., Roberson E.D., Duan S., Cao L., Worley L.A., Council M.L., Matatall K.A., Helms C. and Bowcock A.M. (2010). Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413.
15. Hellmann J., Rommelspacher H., Muhlbauer E. and Wernicke C. (2010). Raf kinase inhibitor protein enhances neuronal differentiation in human SH-SY5Y cells. Dev. Neurosci. 32, 33-46.
16. Krosl ak T., Koch T., Kahl E. and Hol l t V. (2001). Human phosphatidylethanolaminebinding protein facilitates heterotrimeric G protein-dependent signaling. J. Biol. Chem. 276, 39772-39778.
17. Leonardi R., Loreto C., Talic N., Caltabiano R. and Musumeci G. (2012). Immunolocalization of lubricin in the rat periodontal ligament during experimental tooth movement. Acta Histochem. 114, 700-704.
18. Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M., Liu Y.X., Yang J. and Yao Z. (2008). Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol. Cancer Res. 6, 917-928.
19. Li H.Z., Gao Y., Zhao X.L., Liu Y.X., Sun B.C., Yang J., and Yao Z. (2009). Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol. Cancer Res. 7, 832-840
20. Lorenz K., Lohse M.J., and Quitterer U. (2003). Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426, 574-579.
21. Margo C.E. and McLean I.W. (1984). Malignant melanoma of the choroid and ciliary body in black patients. Arch. Ophthalmol. 102, 77-79.
22. McLean I.W., Foster W.D., Zimmerman L.E. and Gamel J.W. (1983). Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am. J. Ophthalmol. 96, 502-509.
23. Onken M.D., Worley L.A., Ehlers J.P. and Harbour J.W. (2004). Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64, 7205-7209.
24. Park S., Yeung M.L., Beach S., Shields J.M. and Yeung K.C. (2005). RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24, 3535-3540.
25. Prescher G., Bornfeld N., Hirche H., Horsthemke B., Jöckel K.H. and Becher R. (1996). Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347, 1222-1225.
26. Reddy K.B., Nabha S.M. and Atanaskova N. (2003). Role of MAP kinase in tumour progression and invasion. Cancer Metastasis Rev. 22, 395-403.
27. Schuierer M.M., Bataille F., Hagan S., Kolch W. and Bosserhoff A.K. (2004). Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 64, 5186-5192.
28. Serre L., Pereira de Jesus K., Zelwer C., Bureaud N., Schoentgen F., and Benedetti H., (2001). Crystal structures of YBHB and YBCL form Escherichia coli, two bacterial homologues to a Raf kinase inhibitor protein. J. Mol. Biol. 310, 617-634.
29. Shah C.P., Weis E., Lajous M., Shields J.A. and Shields C.L. (2005). Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology. 112, 1599-1607.
30. Singh A.D. and Topham A. (2003). Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 110, 962-965.
31. Spagnolo F., Caltabiano G. and Queirolo P. (2012). Uveal melanoma. Cancer Treat. Rev. 38, 549-553.
32. Wu K. and Bonavida B. (2009). The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit. Rev. Immunol. 29, 241-254.
33. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M. and Kolch W. (1999). Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401, 173-177.
34. Yeung K., Janosch P., McFerran B., Rose D.W., Mischak H., Sedivy J.M. and Kolch W. (2000). Mechanism of suppression of the Raf/MEK/extracellular signalregulated kinase pathway by the raf kinase inhibitor protein. Mol. Cell. Biol. 20, 3079-3085.
35. Yeung K.C., Rose D.W., Dhillon A.S., Yaros D., Gustafsson M., Chatterjee D., Mc Ferran B., Wyche J., Kolch W. and Sedivy J.M. (2001). Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol. Cell. Biol. 21, 7207-7217.